Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical information in Blood Advances, the open up-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natural killer (NK) prison cell function and proliferation in multiple myeloma (MM).

"These findings published today in Blood Advances demonstrate the promising anti-tumor activity of IL-15 in engaging natural killer cell biology in indications with immunosuppressive tumor microenvironments as in multiple myeloma," said Nikhil C. Munshi, MD, Professor of Medicine at Harvard Medical School, Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Heart at Dana-Farber Cancer Plant. "Amidst other immune cells, the NK cell expansion and improved part induced by NKTR-255 is contributing to more than effective control of multiple myeloma tumor growth, raising a potential scope for synergism with other anti-MM therapies such as anti-CD38 antibodies."

The Dana-Farber squad analyzed in vitro pharmacological properties of NKTR-255 in engaging the IL-xv pathway and stimulating NK cells against MM cells. The enquiry also looked at the anti-tumor activity of combining NKTR-255 with the anti-CD38 antibody, daratumumab, in vitro and in vivo.

"The published data demonstrate that NKTR-255 not just enhances antitumor responses of human being NK cells against MM target cells, but likewise increases ex vivo expression of NK activating receptors and adhesion molecules. Furthermore, studies in a humanized MM mouse model show that NKTR-255 enhances in vitro antibiotic-dependent cellular cytotoxicity (ADCC) of NK cells and synergizes with daratumumab to reduce MM cell growth," said Mariateresa Fulciniti, Ph.D., the senior author on this manuscript at Dana-Farber. These preclinical findings back up Nektar's robust clinical development program for NKTR-255 and further evaluation of the novel immunotherapeutic approach in MM, alone or in combination with monoclonal antibodies or potentially with other immunomodulatory drugs.

Key findings are summarized beneath:

NKTR-255 enhances antitumor responses of myeloma derived human NK cells against MM target cells.
NKTR-255 enhances in vitro ADCC of NK cells and synergizes with daratumumab to reduce MM growth in humanized mouse model.
NKTR-255 increases ex vivo expression of NK activating receptors and adhesion molecules.
Augmenting NK jail cell number and functions shows effectiveness confronting MM cells in the context of their bone marrow milieu.

The full citation of this article can be accessed here.

About NKTR-255

NKTR-255 is a biologic that targets the IL-fifteen pathway in society to activate the body's innate and adaptive immunity. Through optimal engagement of the IL-xv receptor complex, NKTR-255 is designed to enhance functional NK jail cell populations and formation of long-term immunological memory, which may pb to sustained and durable anti-tumor immune response.

Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules too equally to raise Automobile-T therapies. Nektar has initiated a Stage 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory not-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/two clinical report of NKTR-255 in patients with relapsed or refractory caput and neck squamous cell carcinoma or colorectal cancer. Nektar is too continuing its oncology clinical collaboration with Merck KGaA and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. Nektar is likewise currently designing a Nektar- sponsored Phase 2 study combining NKTR-255 with approved CAR-T prison cell therapies in diffuse large B-jail cell lymphoma, which it aims to initiate in the offset quarter of 2023.

Well-nigh Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and inflammatory diseases too as a portfolio of canonical partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information most the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Frontwards-Looking Statements

This press release contains forward-looking statements which tin exist identified past words such as: "will," "may," "demonstrate," "potential," "designed," "initiate," "aim" and similar references to future periods. Examples of frontwards-looking statements include, amidst others, statements we make regarding the therapeutic potential of, and futurity evolution plans for NKTR-255 and our other drug candidates in research programs, the prospects and plans for our collaborations with other companies, and the timing of the initiation of clinical studies and the information readouts for our drug candidates. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current behavior, expectations and assumptions regarding the future of our business concern, future plans and strategies, anticipated events and trends, the economic system and other future conditions. Because forward-looking statements relate to the future, they are bailiwick to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our command. Our actual results may differ materially from those indicated in the forwards-looking statements. Therefore, you should non rely on whatever of these forward-looking statements. Of import factors that could cause our bodily results to differ materially from those indicated in the forrad-looking statements include, amongst others: (i) our statements regarding the therapeutic potential of NKTR-255 and our other drug candidates are based on preclinical and clinical findings and observations and are subject to change as enquiry and development go on; (ii) NKTR-255 and our other drug candidates are investigational agents and continued inquiry and evolution for these drug candidates is subject to substantial risks, including negative rubber and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (three) NKTR-255 and our other drug candidates are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to challenges caused by the COVID-19 pandemic, regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approving in one or more of import markets; (5) nosotros may not reach the expected costs savings we expect from our corporate restructuring and reorganization, (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) sure other important risks and uncertainties set forth in our Quarterly Written report on Class x-Q filed with the Securities and Exchange Commission on August 5, 2022. Whatsoever forward-looking statement made by us in this press release is based only on information currently available to us and speaks only every bit of the date on which information technology is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may exist made from time to time, whether as a event of new information, hereafter developments or otherwise.

Contact:
Vivian Wu of Nektar Therapeutics
628-895-0661

SOURCE Nektar Therapeutics

Source: https://www.prnewswire.com/news-releases/nektar-and-collaborators-announce-preclinical-publication-of-data-for-nktr-255-and-its-observed-improvement-of-nk-cell-function-in-multiple-myeloma-301606100.html

Posted by: pimentelpoppershe.blogspot.com